Abstract The 2022 World Health Organization (WHO) classification of the urinary and male
genital tumors was recently published by the International Agency for Research on Cancer …

This Seminar presents the current best practice for the diagnosis and management of
bladder cancer. The scope of this Seminar ranges from current challenges in pathology …

Context This overview presents the updated European Association of Urology (EAU)
guidelines for non–muscle-invasive bladder cancer (NMIBC), TaT1, and carcinoma in situ …

It has been 12 yr since the publication of the last World Health Organization (WHO)
classification of tumours of the prostate and bladder. During this time, significant new …

A vast range of disorders—from indolent to fast-growing lesions—are labelled as cancer.
Therefore, we believe that several changes should be made to the approach to cancer …

In Europe, an estimated 151 297 new cases of bladder cancer were diagnosed in 2012, with
an age-standardised incidence rate (per 100000 persons) of 17.7 for males and 3.5 for …

Context Tumour grade is an important prognostic indicator in non–muscle-invasive bladder
cancer (NMIBC). Histopathological classifications are limited by interobserver variability …

Over the past 30years, awareness and screening have led to an emphasis on early
diagnosis of cancer. Although the goals of these efforts were to reduce the rate oflate …

Bladder cancer is a complex disease associated with high morbidity and mortality rates if not
treated optimally. Awareness of haematuria as the major presenting symptom is paramount …

Bladder cancer is a heterogeneous disease, with 70% of patients presenting with superficial
tumours, which tend to recur but are generally not life threatening, and 30% presenting as …